Fig. 6: Heatmap representation of published immune cells gene signatures expression at pre- and post-treatment (n = 19). | Nature Communications

Fig. 6: Heatmap representation of published immune cells gene signatures expression at pre- and post-treatment (n = 19).

From: Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial

Fig. 6

The mRECIST categories were defined as SD (Stable Disease), PR (Partial Response), and CR (Complete Response); CLD represents the assessment of the change in the longest diameter according to mRECIST criteria. Patient bar labeled by patient ID. The heatmap illustrates the scaled values derived from the gene expression data, ranging from blue to red, indicating increasing values. Blue represents patients at pre-treatment, and red represents patients at post-treatment. Source data are provided as a Source Data file.

Back to article page